Laidlaw assumed coverage on shares of ZIOPHARM Oncology (NASDAQ:ZIOP) in a research note released on Monday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $7.50 price target on the biotechnology company’s stock.
ZIOP has been the topic of a number of other research reports. BidaskClub raised ZIOPHARM Oncology from a buy rating to a strong-buy rating in a research report on Wednesday, March 20th. Zacks Investment Research lowered ZIOPHARM Oncology from a buy rating to a hold rating in a research report on Thursday, December 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $5.56.
NASDAQ ZIOP opened at $3.98 on Monday. The stock has a market cap of $624.83 million, a PE ratio of -8.29 and a beta of 2.62. ZIOPHARM Oncology has a one year low of $1.56 and a one year high of $5.00.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Featured Article: Terms to Better Understand Call Options
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.